-
Mashup Score: 0
Welcome! You are invited to join a webinar: Measuring the return from pharmaceutical innovation 2022. After registering, you will receive a confirmation email about joining the webinar.
Source: ZoomCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 2Measuring the return from pharmaceutical innovation 2021 - 1 year(s) ago
Our latest report looks at the current state of R&D returns for 15 leading biopharma companies from May 2019 to April 2020, the impact of the pandemic on R&D pipelines during 2020 and identifies lessons that can help change the R&D paradigm towards a future with higher returns.
Source: Deloitte United StatesCategories: Future of Medicine, Latest HeadlinesTweet-
The average cost to develop an asset from discovery to launch has increased, while peak sales forecasts have declined compared to 2021. Find out why in our latest #BioPharma innovation report. https://t.co/x7AfyoPtZ7 https://t.co/RY1tpXGbwa
-
-
Mashup Score: 0Seven Biopharma Trends to Watch in 2023 - 1 year(s) ago
Key trends include fewer and slower financings, a surge of decisive data readouts for cancer vaccines, and further development of mRNA, cell, and gene therapies.
Categories: Future of Medicine, Latest HeadlinesTweet-
Seven #Biopharma Trends to Watch in 2023 Key trends include fewer and slower financings, a surge of decisive data readouts for #cancer #vaccines, and further development of #mRNA, cell, and #genetherapies. Learn more: https://t.co/ht44M05bVp https://t.co/ma9miJhrmx
-
-
Mashup Score: 0PharmStars - 1 year(s) ago
PharmStars is the first and only pharma-focused accelerator for digital health startups, dedicated to driving digital health adoption to improve patient outcomes.
Source: www.pharmstars.comCategories: Future of Medicine, Latest HeadlinesTweet-
Learn how #digitalhealth #startups can connect to #pharma in this @HIMSS interview about @PharmStars' #acceleratorprogram-- the most effective way for startups to learn about & gain access to large #biopharma. Apply by 1/14 at https://t.co/MPl6gbTBwE https://t.co/iIuVSjw8g3
-
-
Mashup Score: 0Most-read First Opinion essays of 2022 - 1 year(s) ago
If you like reading opinion/perspective essays, check out the most-read First Opinion essays from 2022.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
STAT published nearly 500 First Opinion essays this year, written by more than 700 authors from the #biopharma industry, #healthcare, academia, government and private life in the U.S. and beyond. Here are the most-read essays of 2022: https://t.co/CmX6sF8hcQ
-
-
Mashup Score: 0
The list of the worst biopharma CEOs of 2022: No “winner,” just accountability, @adamfeuerstein writes.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
The list of the worst #biopharma CEOs of 2022: No ‘winner,’ just accountability. https://t.co/QPQrMMkjy6 via @adamfeuerstein
-
-
Mashup Score: 3
The list of the worst biopharma CEOs of 2022: No “winner,” just accountability, @adamfeuerstein writes.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
The list of the worst #biopharma CEOs of 2022: No ‘winner,’ just accountability https://t.co/QIiLmP4Ecs
-
-
Mashup Score: 0
Nods to the CEOs behind some of this year’s biggest biopharma deals and most exciting new drug treatments.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
.@adamfeuerstein has his finalists for best #biopharma CEO of 2022. See who's at the top of the list: https://t.co/sHHmomgrYF
-
-
Mashup Score: 0Inside The Modular Factory Set to Disrupt Cell Therapy | United States Of Automation - 1 year(s) ago
Content produced by Insider Studios. Sponsored by AT&T Business.Manufacturing cell therapies can save lives – but on long timelines, owing to the labor-inten…
Source: YouTubeCategories: Healthcare Professionals, Latest HeadlinesTweet-
“Cell therapy manufacturing reimagined – delivering real cost savings, efficiencies and true scalability.“ Cellares 👉 https://t.co/9obtsuZUMx @ATTBusiness #ATTinfluencer #manufacturing #healthtech #LifeSciences #celltherapy #biopharma
-
-
Mashup Score: 1
Amgen has agreed to acquire Horizon Therapeutics for approximately $27.8 billion, the year’s biggest biopharma acquisition deal to date.
Categories: Future of Medicine, Latest HeadlinesTweet-
.@Amgen has agreed to acquire @HorizonNews for approximately $27.8 billion, the year’s biggest #biopharma acquisition deal to date, intended to replenish the buyer’s rare autoimmune, and inflammatory disease portfolios...Read more: https://t.co/miFvcsEMrS https://t.co/2y45iJ5IWM
-
Deloitte’s annual report on measuring the return from pharmaceutical innovation has provided insights into the state of #BioPharma R&D since 2010. Join us Feb. 28 from 10-11 AM/ET to learn more. https://t.co/dJ3bYAqvqT